Jeffery Kutok - Aug 16, 2021 Form 4 Insider Report for Epizyme, Inc. (EPZM)

Role: Chief Scientific Officer
Signature: /s/ John Weidenbruch, attorney-in-fact
Stock symbol: EPZM
Transactions as of: Aug 16, 2021
Transactions value $: $0
Form type: 4
Date filed: 8/18/2021, 08:09 AM
Next filing: Feb 4, 2022

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	EPZM	Common Stock, par value $0.0001	Award	$0	+45.8K	+84.83%	$0.00	99.9K	Aug 16, 2021	Direct	F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	EPZM	Stock Option (Right to Buy)	Award	$0	+219K		$0.00	219K	Aug 16, 2021	Common Stock	219K	$5.31	Direct	F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Consists of shares of Common Stock issuable under 45,832 restricted stock units ("RSUs") granted pursuant to the Company's 2013 Stock Incentive Plan. Each RSU represents the right to receive one share of Common Stock upon vesting. These RSUs are scheduled to vest in three equal annual installments over three years from the grant date, with the first installment vesting on August 16, 2022.
F2	This option was granted on August 16, 2021 pursuant to the Company's 2013 Stock Incentive Plan with respect to 218,661 shares of Common Stock, with 33.33% vesting on August 16, 2022 and the remaining 66.67% vesting in 24 substantially equal monthly installments thereafter.